Clinical Trials Browser

Breast Carcinoma In Situ × pembrolizumab × 30 days × Clear all

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Phase 3 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms